Introduction & Objective: Patients with type 2 DM have frequently GI signs/symptoms and small intestinal bacterial overgrowth (SIBO), which may impair beta cell function and diabetes control. The study aimed to evaluate the influence of microencapsulated oral sodium butyrate on GI signs, SIBO incidence, and diabetes control.
Methods: In a prospective, randomized, placebo-controlled double-blind study, 52 patients with type 2 DM treated with diet or oral antidibetics (2 pts. on insulin) and abdominal pain were randomly assigned to butyrate 1.5 g/day (n=29) or placebo (n=23) for 12 weeks. Before and after the intervention the presence of abdominal pain, diarrhoea, constipation and flatulence was assessed, laboratory tests and hydrogen breath tests were performed, HbA1c was assessed.
Results: After the intervention in the butyrate group there was significantly more patients relieved from GI signs and symptoms as in the placebo group (Table 1). Additionally, there was a significant decrease of SIBO prevalence in the butyrate group as compared with placebo group. In the patients treated with butyrate a slight but significant improvement of BMI and HbA1C level was also observed (Table 1).
Conclusion: Oral microencapsulated sodium butyrate supplementation is effective in relieving abdominal signs, treating SIBO, improving body mass and metabolic control in patients with type 2 DM.
P. Panufnik: None. M. Wiecek: None. P. Szwarc: None. M. Kaniewska: None. K. Lewandowski: None. E. Franek: Speaker's Bureau; AstraZeneca. Research Support; BIOTON. Speaker's Bureau; BIOTON, Boehringer-Ingelheim, Berlin-Chemie AG, Merck & Co., Inc., Eli Lilly and Company, Novo Nordisk, Sanofi. G. Rydzewska: Speaker's Bureau; AlfaSigma. Consultant; AbbVie Inc. Speaker's Bureau; Bayer Inc., Pfizer Inc. Consultant; Takeda Pharmaceutical Company Limited. Speaker's Bureau; Janssen Pharmaceuticals, Inc.
The sodium butyrate preparation and placebo was provided by the Bioton company.
